Search

Your search keyword '"Grote-Levi, Lea"' showing total 13 results
Start Over Author "Grote-Levi, Lea"
13 results on '"Grote-Levi, Lea"'

4. Combined treatment with allogeneic Epstein–Barr- and human polyomavirus 1 specific T-cells in progressive multifocal leukoencephalopathy and EBV infection: a case report

Author

Nay, Sandra, primary, Möhn, Nora, additional, Grote-Levi, Lea, additional, Bonifacius, Agnes, additional, Saßmann, Mieke L., additional, Karacondi, Kevin, additional, Tischer-Zimmermann, Sabine, additional, Pöter, Henning, additional, Mahmoudi, Nima, additional, Wattjes, Mike P., additional, Maecker-Kolhoff, Britta, additional, Höglinger, Günter, additional, Eiz-Vesper, Britta, additional, and Skripuletz, Thomas, additional

Published
2024
Full Text
View/download PDF

5. Combined high-throughput library screening and next generation RNA sequencing uncover microRNAs controlling human cardiac fibroblast biology

Author

Schimmel, Katharina, Stojanović, Stevan D., Huang, Cheng-Kai, Jung, Mira, Meyer, Martin H., Xiao, Ke, Grote-Levi, Lea, Bär, Christian, Pfanne, Angelika, Mitzka, Saskia, Just, Annette, Geffers, Robert, Bock, Katharina, Kenneweg, Franziska, Kleemiß, Felix, Falk, Christine S., Fiedler, Jan, and Thum, Thomas

Published
2021
Full Text
View/download PDF

6. Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy

Author

Grote-Levi, Lea, primary, Möhn, Nora, additional, Bonifacius, Agnes, additional, Tischer-Zimmermann, Sabine, additional, Schweitzer, Finja, additional, Mahmoudi, Nima, additional, Silling, Steffi, additional, Warnke, Clemens, additional, Maecker-Kolhoff, Britta, additional, Wattjes, Mike P., additional, Eiz-Vesper, Britta, additional, Höglinger, Günter U., additional, and Skripuletz, Thomas, additional

Published
2023
Full Text
View/download PDF

8. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

Author

Schimmel, Katharina, Jung, Mira, Foinquinos, Ariana, José, Gorka San, Beaumont, Javier, Bock, Katharina, Grote-Levi, Lea, Xiao, Ke, Bär, Christian, Pfanne, Angelika, Just, Annette, Zimmer, Karina, Ngoy, Soeun, López, Begoña, Ravassa, Susana, Samolovac, Sabine, Janssen-Peters, Heike, Remke, Janet, Scherf, Kristian, Dangwal, Seema, Piccoli, Maria-Teresa, Kleemiss, Felix, Kreutzer, Fabian Philipp, Kenneweg, Franziska, Leonardy, Julia, Hobuß, Lisa, Santer, Laura, Do, Quoc-Tuan, Geffers, Robert, Braesen, Jan Hinrich, Schmitz, Jessica, Brandenberger, Christina, Müller, Dominik N., Wilck, Nicola, Kaever, Volkhard, Bähre, Heike, Batkai, Sandor, Fiedler, Jan, Alexander, Kevin M., Wertheim, Bradley M., Fisch, Sudeshna, Liao, Ronglih, Diez, Javier, González, Arantxa, and Thum, Thomas

Published
2020
Full Text
View/download PDF

10. Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications

Author

Konen, Franz Felix, primary, Schwenkenbecher, Philipp, additional, Jendretzky, Konstantin Fritz, additional, Gingele, Stefan, additional, Grote-Levi, Lea, additional, Möhn, Nora, additional, Sühs, Kurt-Wolfram, additional, Eiz-Vesper, Britta, additional, Maecker-Kolhoff, Britta, additional, Trebst, Corinna, additional, Skripuletz, Thomas, additional, and Hümmert, Martin W., additional

Published
2022
Full Text
View/download PDF

11. Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity.

Author

Möhn, Nora, Mahjoub, Susann, Duzzi, Laura, Narten, Emily, Grote‐Levi, Lea, Körner, Gudrun, Seeliger, Tabea, Beutel, Gernot, Bollmann, Benjamin‐Alexander, Wirth, Thomas, Huss, André, Tumani, Hayrettin, Grimmelmann, Imke, Gutzmer, Ralf, Ivanyi, Philipp, and Skripuletz, Thomas

Subjects
MONOCYTE chemotactic factor, IMMUNE checkpoint proteins, DRUG side effects, IPILIMUMAB, BRAIN-derived neurotrophic factor, IMMUNE checkpoint inhibitors, MONOCLONAL gammopathies
Abstract

Background: Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological adverse events (nAE(+)), are tough to diagnose and biomarkers to identify patients at risk are missing. Methods: A prospective register with prespecified examinations was established for ICI treated patients in December 2019. At the time of data cut‐off, 110 patients were enrolled and completed the clinical protocol. Herein, cytokines and serum neurofilament light chain (sNFL) from 21 patients were analyzed. Results: nAE of any grade were observed in 31% of the patients (n = 34/110). In nAE(+) patients a significant increase in sNFL concentrations over time was observed. Patients with higher‐grade nAE had significantly elevated serum‐concentrations of monocyte chemoattractant protein 1 (MCP‐1) and brain‐derived neurotrophic factor (BDNF) at baseline compared to individuals without any nAE (p < 0.01 and p < 0.05). Conclusion: Here, we identified nAE to occur more frequently than previously reported. Increase of sNFL during nAE confirms the clinical diagnosis of neurotoxicity and might be a suitable marker for neuronal damage associated with ICI therapy. Furthermore, MCP‐1 and BDNF are potentially the first clinical‐class nAE predictors for patients under ICI therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report.

Author

Grote-Levi L, Möhn N, Bonifacius A, Tischer-Zimmermann S, Schweitzer F, Mahmoudi N, Silling S, Warnke C, Maecker-Kolhoff B, Wattjes MP, Eiz-Vesper B, Höglinger GU, and Skripuletz T

Subjects
Humans, Cerebellum, Atrophy, Cell- and Tissue-Based Therapy, JC Virus, Hematopoietic Stem Cell Transplantation
Abstract

Objectives: JC virus granule cell neuronopathy is a potentially fatal otherwise highly disabling disease without an approved therapeutic option. This case report presents the positive record to T-cell therapy in JC virus granule cell neuronopathy., Methods: The patient represented with subacute cerebellar symptoms. Diagnosis of JC virus granule cell neuronopathy was made because of infratentorially accentuated brain volume atrophy shown by brain MRI and the detection of JC virus DNA in the CSF., Results: Six doses of virus-specific T cells were administered. Within 12 months after therapy initiation, the patient showed clear clinical benefit with improvement of symptoms, and JC viral DNA load significantly declined., Discussion: We present the case report of a positive response to T-cell therapy in JC virus granule cell neuronopathy, leading to an improvement of symptoms., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results